Vonicog alfa is currently in clinical development for the prevention (prophylaxis) of bleeding episodes in patients with von Willebrand disease (VWD). VWD is a genetic bleeding disorder caused by a deficiency or absence of a blood clotting factor, called the von Willebrand factor. This causes poor blood clotting, which results in difficulty in stopping the flow of blood from a wound, causing prolonged bleeding. Current therapy includes preventative (prophylactic) treatment where medicine is used to prevent bleeding, or on-demand treatment, where medicine is used to treat prolonged bleeding.
Vonicog alfa for Prophylaxis of Haemorrhage in Von Willebrand disease
![featured image](https://www.io.nihr.ac.uk/wp-content/uploads/2022/01/Partners-Industry_Motifs_Motifs_Conduction-broadcasting_RGB-scaled_edited_1233.jpg)
Vonicog alfa is currently in clinical development for the prevention (prophylaxis) of bleeding episodes in patients with von Willebrand disease (VWD). VWD is a genetic bleeding disorder caused by a deficiency or absence of a blood clotting factor, called the von Willebrand factor.
Interventions:
Vonicog alfa (recombinant von Willebrand factor)
Indications:
von Willebrand disease
Year:
2023